The Prognostic Role of Body Mass Index on Oncological Outcomes of Upper Tract Urothelial Carcinoma

Simple Summary In patients with upper tract urothelial carcinoma, the impact of body mass index on oncological outcomes is still a matter of debate. We use the Clinical Research Office of the Endourology Society Urothelial Carcinomas of the Upper Tract Registry to compare the overall survival, cancer-specific survival, and recurrence-free survival between normal weight, overweight and obese patients. After balancing the clinicopathological features by propensity score matching, being overweight/obese (body mass index ≥ 25.0 kg/m2) was associated with a decreased risk of recurrence in upper tract urothelial carcinoma patients but not overall survival or cancer-specific survival. Abstract (1) Objective: The aim of this study was to evaluate whether overweight and obese upper urinary tract carcinoma (UTUC) patients have better or worse survival outcomes. (2) Methods: The Clinical Research Office of the Endourology Society Urothelial Carcinomas of the Upper Tract (CROES-UTUC) Registry was used to extract the data of normal-weight or overweight/obese UTUC patients between 2014 and 2019. Patients with a BMI between 18.5 and 24.9 kg/m2 were defined as normal weight, while those with a BMI ≥ 25.0 kg/m2 were considered as overweight/obese group. We compared baseline characteristics among groups categorized by different BMIs. The Kaplan–Meier plots with the log-rank test were used to explore the overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Propensity score matching was performed to eliminate the differences in clinicopathologic features. The Declaration of Helsinki was followed during this study. (3) Results: Of 1196 UTUC patients, 486 patients (40.6%) were normal weight, while 710 patients (59.4%) presented with a BMI ≥ 25.0 kg/m2. After propensity score matching, all baseline characteristics were balanced. For normal weight and overweight/obese patients, 2-year overall survival rates were 77.8% and 87.2%, 2-year cancer-specific survival rates were 85.2% and 92.7%, and 2-year recurrence rates were 50.6% and 73.0%, respectively. The overweight patients obtained a better RFS (p = 0.003, HR 0.548, 95% CI 0.368–0.916) while their OS (p = 0.373, HR 0.761, 95% CI 0.416–1.390) and CSS (p = 0.272, HR 0.640, 95% CI 0.287–1.427) were similar to normal weight patients. (4) Conclusions: Being overweight/obese (BMI ≥ 25.0 kg/m2) was associated with a decreased risk of recurrence in UTUC patients but not overall survival or cancer-specific survival.

[1]  T. Afxentiou,et al.  A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer. , 2022, European journal of cancer.

[2]  A. Wallin,et al.  Testosterone associates differently with body mass index and age in serum and cerebrospinal fluid in men , 2022, Journal of internal medicine.

[3]  Yijian Li,et al.  Construction and Verification of Immunohistochemistry Parameters-Based Classifier to Predict Local-Recurrence of Upper Tract Urothelial Carcinoma After Kidney-Sparing Surgery , 2022, Frontiers in Oncology.

[4]  Xuefeng Liu,et al.  Reduced Preoperative Glomerular Filtration Rate Is Associated With Adverse Postoperative Oncological Prognosis in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Retrospective Cohort Study , 2022, Frontiers in Surgery.

[5]  L. Downey,et al.  Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis , 2022, European urology open science.

[6]  Liqun Zhou,et al.  Effectiveness of adjuvant radiotherapy for high recurrence risk patients with upper tract urothelial carcinoma. , 2022, Urologic oncology.

[7]  F. Montorsi,et al.  The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy. , 2022, European urology oncology.

[8]  A. Batra,et al.  Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis. , 2022, Cancer treatment and research communications.

[9]  T. Key,et al.  Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies , 2021, BMC Medicine.

[10]  S. Shariat,et al.  Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry , 2021, Current opinion in urology.

[11]  T. Choueiri,et al.  Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. , 2021, JAMA oncology.

[12]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[13]  P. Han,et al.  The Prognostic Value of Body Mass Index in Patients With Urothelial Carcinoma After Surgery: A Systematic Review and Meta-Analysis , 2020, Dose-response : a publication of International Hormesis Society.

[14]  C. Reid,et al.  Sociodemographic, lifestyle and medical influences on serum testosterone and sex hormone–binding globulin in men from UK Biobank , 2020, Clinical endocrinology.

[15]  Y. Lotan,et al.  Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy , 2020, World Journal of Urology.

[16]  D. Matsuda,et al.  Impact of body mass index on the oncological outcomes of patients with upper and lower urinary tract cancers treated with radical surgery: A multi‐institutional retrospective study , 2018, Asia-Pacific journal of clinical oncology.

[17]  M. Eisenhut,et al.  Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  T. Hansen,et al.  Causal relationship between obesity and serum testosterone status in men: A bi-directional mendelian randomization analysis , 2017, PloS one.

[19]  S. Signoretti,et al.  Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Flaig,et al.  The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma. , 2016, Current drug targets.

[21]  F. Saad,et al.  Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. , 2014, Urologic oncology.

[22]  H. Azuma,et al.  Specific body mass index cut-off value in relation to survival of patients with upper urinary tract urothelial carcinomas , 2012, International Journal of Clinical Oncology.

[23]  W. Lowrance,et al.  Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. , 2011, The Journal of urology.

[24]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[25]  A Keys,et al.  Indices of relative weight and obesity. , 1972, Journal of chronic diseases.

[26]  M. Sibony,et al.  Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma , 2017, World Journal of Urology.